Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Ben Stevens · page 22
- UK & Europe
‘No One Expected the Surge’: Grunhorn on How Telemedicine Took German Medical Cannabis by Storm
Since April 2024, Germany has been firmly cemented at the centre of the global cannabis conversation, and for good reason.
- Investment & Finance
UK Clinic Releaf Expands into Germany, Aiming for Top Spot Within Six Months
UK clinic Releaf expands into Germany, leveraging its digital health ecosystem to capture market share in Europe’s fast-growing medical cannabis sector.
- US & Canada
New York CCB Unanimously Votes to Overturn ‘Unreasonable’ Local Cannabis Rules
New York’s Cannabis Control Board (CCB) has unanimously overturned Southampton’s restrictive cannabis ordinances, ruling that the town’s permitting scheme was illegal and designed to prevent legal dispensaries from opening.
- US & Canada
New York Court Blocks State From Forcing Dispensary Relocations
More than 150 licensed cannabis dispensaries across New York are protected from forced relocation or closure following a preliminary injunction issued by the state’s Supreme Court against the Office of Cannabis Management (OCM).
- International Regulation
Inside Australia’s Medical Cannabis Boom: Prescriptions, Products & Patients
Australia’s thriving medical cannabis industry has continued its blistering levels of growth, seeing the amount of medical cannabis imported grow nearly tenfold in just three years, according to new official data.
- Investment & Finance
Trump Sends Cannabis Stocks Surging, Cantourage Brings in Investor Relations Help, & Mamedica Secures £4.5m
Cannabis Stocks Surge on Trump Video Global cannabis stocks have enjoyed a considerable, but likely temporary, run this week, after US President Donald Trump shared a video apparently endorsing the use of CBD for senior healthcare.
- UK & Europe
What Does the First Official Data on Germany’s Cannabis Reforms Show?
Germany’s booming cannabis market, which Prohibition Partners now estimates to be worth around €670m, is entering uncertain and potentially treacherous territory.
- Opinion
Trump Just Put Cannabinoids Back in the Spotlight — Science Might Finally Catch Up
This opinion piece was written by Calvin Rasode, Vice President, Marketing, Brains Bioceutical When Donald Trump tweets, the world pays attention.
- Opinion
Authenticity Over Artificial: A European Approach to Cannabis Products
In the latest instalment of our series spotlighting expert contributors to Prohibition Partners’ newly launched Insights Hub, we spoke with Terpene Belt Farms about how European cannabis brands can draw on the continent’s rich culinary and cultural traditions to build authentic, consumer-trusted products.
- Retail & Brands
Are Rival’s Challenges to High Tide’s German Entry About Compliance Or Competition?
Last month, one of Canada’s largest cannabis retailers, High Tide, thrust its way into the booming German medical cannabis market by acquiring a majority stake in Remexian Pharma GmbH in a deal worth over €27m.
- Companies
Curaleaf Partners with Medical Cannabis Clinicians Society to Strengthen UK Prescriber Education
The UK’s medical cannabis industry is now the second largest in Europe, second only to Germany, thanks to consistent and sustained growth over the last seven years.
- Companies
Astrasana Launches Ast-Premium Line: Hand-Selected Cannabis Flowers for Patients in More Than 20 Pharmacies Across Switzerland
Astrasana Holding AG is introducing its AST-Premium Line, a new range of premium-quality cannabis flowers, to the Swiss market.
